Changing PMA or HDE Devices During COVID-19

by | May 29, 2020 | Coronavirus, COVID-19, FDA, Medical Devices, Quality Systems, Requirements

As medical device firms adjust to the new normal in light of COVID-19 hurdles, the FDA continues to issue guidances and relax regulatory requirements to accommodate. Disruptions to global supplies and the challenge of social distance restrictions may be the driving forces behind necessary device and operations changes. Normally, the FDA requires manufacturers to file a supplement or 30-day notice for their premarket approvals (PMA) or humanitarian device exemptions (HDE) before implementing changes.1 With the constraints the global pandemic has put on the medical device industry, the agency issued a guidance last week relaxing that requirement for certain design changes.

The guidance on supplements for PMA and HDE submissions during COVID-19 identifies that manufacturers may need to make immediate changes to manufacturing processes to overcome COVID-19 complications. The FDA is relaxing regulatory requirements for a specific set of changes that the industry has identified as necessary to mitigate limitations seen during the public health emergency. Some of these changes may be adjusting manufacturing processes to allow for social distancing among workers, adapting processes or device design due to supply chain disruption, or even moving device production to a different location less impacted by the pandemic. The agency is allowing firms to make these changes without prior notification as long as they do not create undue risk. Changes that the FDA has identified as potentially creating undue risk, and therefore require the standard notification, include changes to sterilization methods, changes to the intended use of the device, and automation of a manufacturing process that is not fully verified.2

The guidance explains that the FDA expects all changes to be documented in change control and device master records. Any component change must also have the required verification/validation testing and reference the applicable standards or specifications to which the component conforms. It is also highly recommended that manufacturers fully identify and describe any changes made without prior notification during the public health emergency.

As the medical device industry continues to adjust to operations during COVID-19, the FDA is working diligently to lessen burdens on the industry by temporarily relaxing certain regulatory requirements. If you need guidance on what regulations to follow during the pandemic, EMMA International is ready to help you navigate. Give us a call at 248-987-4497 or email info@emmainternational.com to see how we can help.


1FDA (December 2019) 30-Day Notices, 135-Day PMA Supplements and 75-Day HDE Supplements for Manufacturing Method or Process Changes retrieved on 05/27/2020 from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/30-day-notices-135-day-premarket-approval-pma-supplements-and-75-day-humanitarian-device-exemption

2FDA (May 2020) Supplements for PMA or HDE Submissions during the COVID-19 Public Health Emergency retrieved on 05/27/2020 from: https://www.fda.gov/media/138265/download

Madison Wheeler

Madison Wheeler

Director of Technical Operations - Ms. Wheeler serves as EMMA International’s Director of Technical Operations. She has experience in technical writing, nonconforming product management, issue evaluations, and implementing corrective and preventative actions in the pharmaceuticals and medical device industries. She has experience cross-functionally between R&D, lean manufacturing operations, and RA compliance. Ms. Wheeler also has academic and work experience with human health-risk engineering controls, physiological biophysics, and clinical research. Ms. Wheeler holds a Bachelor of Science in Biosystems Engineering with a concentration in Biomedical Engineering from Michigan State University. She is also a Certified Quality Auditor (CQA), and is currently pursuing her M.S. in Quality Management.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This